Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Free Cash Flow: 2016-2024

Historic Free Cash Flow for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$32.8 million.

  • Mereo BioPharma Group's Free Cash Flow rose 2.79% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 8.36%. This contributed to the annual value of -$32.8 million for FY2024, which is 55.38% down from last year.
  • As of FY2024, Mereo BioPharma Group's Free Cash Flow stood at -$32.8 million, which was down 55.38% from -$21.1 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Free Cash Flow registered a high of -$7.8 million during FY2021, and its lowest value of -$48.8 million during FY2022.
  • For the 3-year period, Mereo BioPharma Group's Free Cash Flow averaged around -$34.3 million, with its median value being -$32.8 million (2024).
  • Per our database at Business Quant, Mereo BioPharma Group's Free Cash Flow skyrocketed by 78.63% in 2021 and then tumbled by 527.41% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Free Cash Flow stood at -$36.4 million in 2020, then soared by 78.63% to -$7.8 million in 2021, then plummeted by 527.41% to -$48.8 million in 2022, then spiked by 56.73% to -$21.1 million in 2023, then tumbled by 55.38% to -$32.8 million in 2024.